A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis

Rheumatology

Volumn 39, Issue 3, 2000, Pages 316-320

  Lerndal, T ^a   Svensson, B ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Spenshult Hospital for Rheumatic Diseases   (Sweden)

Author keywords

CPH 82; Methotrexate; Rheumatoid arthritis; Semi synthetic lignan glycosides; Therapy

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CORTICOSTEROID; CPH 82; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; HYPERHIDROSIS; LEUKOPENIA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 0034032210     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.3.316     Document Type: Article

References (14)

1. Larsen A, Petersson I, Svensson B. Podophyllum derivatives (CPH 82) compared with placebo in the treatment of rheumatoid arthritis. Br J Rheumatol 1989;28:124-7.
2. Hedin PJ, Pettersson B. Treatment of rheumatoid arthritis with Reumacon. A placebo controlled study. Scand J Rheumatol 1990;85:48(abstract).
3. Larsson L-G, Goobar J, Olhagen B. A double-blind randomized trial of CPH 82 (Reumacon) and sulpha-salazine in rheumatoid arthritis. Scand J Rheumatol 1990;85:56(abstract).
4. Bjoørneboe B, Moen F, Nygaard H, Haavik TK, Svensson B. CPH 82 (Reumacon R) versus Auranofin (Ridaura R). A 36-week study of their respective onset of action rates in RA. Scand J Rheumatol 1998;27:26-31.
5. Korpela M, Tiitinen S, Nissilä M. Clinical open study of podophyllotoxin derivative (CPH 82) versus azathioprine in treatment of rheumatoid arthritis and reactive (AA) amyloidosis. Abstract. Scand J Rheumatol 1998; 27(suppl. 108): 120.
6. Weinblatt ME, Coblyn JS, Fox DA et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985;312:818-22.
7. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
8. Ritchie DM, Boyle JA, Mclnnes JM et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968;147:393-406.
9. Fries JF. The assessment of disability: From first to future principles. Br J Rheumatol 1983;22:48-58.
10. Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Scand J Rheumatol 1988;17:263-71.
11. van Gestel AM, Haagsma CJ, van Riel PLCM. Validation or rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
12. Felson DT, Andersson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
13. R) in patients with rheumatoid arthritis. Scand J Rheumatol 2000;29: in press.
14. Kremer JM, Alarcón GS, Lightfoot Jr RW et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316-28.